
Sign up to save your podcasts
Or


Axios Re:Cap is revisiting some of this year’s biggest stories and what they say about where technology, business, politics and more are headed in 2022.
Alison Snyder, managing editor and author of Axios Science, joins Axios Re:Cap senior producer Naomi Shavin to discuss a major research trend that flew under the radar this year: increased public and private funding for trials looking into therapeutic psychedelics.
By Axios4.3
689689 ratings
Axios Re:Cap is revisiting some of this year’s biggest stories and what they say about where technology, business, politics and more are headed in 2022.
Alison Snyder, managing editor and author of Axios Science, joins Axios Re:Cap senior producer Naomi Shavin to discuss a major research trend that flew under the radar this year: increased public and private funding for trials looking into therapeutic psychedelics.

32,246 Listeners

30,688 Listeners

8,800 Listeners

26,405 Listeners

113,527 Listeners

56,976 Listeners

10,333 Listeners

5,248 Listeners

6,121 Listeners

566 Listeners

5,651 Listeners

10,219 Listeners

6,449 Listeners

2,020 Listeners

5,592 Listeners

4,364 Listeners

16,527 Listeners